IL284779A - Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase - Google Patents
Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinaseInfo
- Publication number
- IL284779A IL284779A IL284779A IL28477921A IL284779A IL 284779 A IL284779 A IL 284779A IL 284779 A IL284779 A IL 284779A IL 28477921 A IL28477921 A IL 28477921A IL 284779 A IL284779 A IL 284779A
- Authority
- IL
- Israel
- Prior art keywords
- gout
- proton
- inhibitor
- treatment
- methods
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010039073 rheumatoid arthritis Diseases 0.000 title 1
- 230000002269 spontaneous effect Effects 0.000 title 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795477P | 2019-01-22 | 2019-01-22 | |
| US201962913270P | 2019-10-10 | 2019-10-10 | |
| PCT/US2020/014346 WO2020154252A1 (en) | 2019-01-22 | 2020-01-21 | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284779A true IL284779A (en) | 2021-08-31 |
Family
ID=69726724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284779A IL284779A (en) | 2019-01-22 | 2021-07-12 | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12544372B2 (https=) |
| EP (1) | EP3914250A1 (https=) |
| JP (3) | JP2022523018A (https=) |
| KR (1) | KR20210119457A (https=) |
| CN (3) | CN113423401A (https=) |
| AU (2) | AU2020213265B2 (https=) |
| CA (1) | CA3125236A1 (https=) |
| IL (1) | IL284779A (https=) |
| MX (2) | MX2021008696A (https=) |
| TW (1) | TW202042815A (https=) |
| WO (1) | WO2020154252A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021249129A1 (en) | 2020-04-03 | 2022-10-20 | F. Hoffmann-La Roche Ag | Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase |
| WO2024235166A1 (zh) * | 2023-05-12 | 2024-11-21 | 武汉人福创新药物研发中心有限公司 | 含有btk抑制剂的组合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362591B (es) * | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| EP4049660B1 (en) | 2016-02-29 | 2025-02-19 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| JP2020514384A (ja) | 2017-03-24 | 2020-05-21 | ジェネンテック， インコーポレイテッド | 自己免疫及び炎症性疾患を治療する方法 |
-
2020
- 2020-01-21 CN CN202080010603.3A patent/CN113423401A/zh active Pending
- 2020-01-21 MX MX2021008696A patent/MX2021008696A/es unknown
- 2020-01-21 EP EP20708271.0A patent/EP3914250A1/en active Pending
- 2020-01-21 TW TW109102194A patent/TW202042815A/zh unknown
- 2020-01-21 JP JP2021542124A patent/JP2022523018A/ja active Pending
- 2020-01-21 CN CN202410640589.5A patent/CN118662512A/zh active Pending
- 2020-01-21 CN CN202410639156.8A patent/CN118453606A/zh active Pending
- 2020-01-21 WO PCT/US2020/014346 patent/WO2020154252A1/en not_active Ceased
- 2020-01-21 AU AU2020213265A patent/AU2020213265B2/en active Active
- 2020-01-21 CA CA3125236A patent/CA3125236A1/en active Pending
- 2020-01-21 KR KR1020217026474A patent/KR20210119457A/ko active Pending
-
2021
- 2021-07-12 IL IL284779A patent/IL284779A/en unknown
- 2021-07-19 MX MX2025013950A patent/MX2025013950A/es unknown
- 2021-07-21 US US17/381,592 patent/US12544372B2/en active Active
-
2024
- 2024-04-09 JP JP2024062648A patent/JP2024099575A/ja active Pending
-
2025
- 2025-03-17 AU AU2025201888A patent/AU2025201888A1/en active Pending
- 2025-11-10 JP JP2025189049A patent/JP2026041743A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020213265A1 (en) | 2021-07-22 |
| MX2025013950A (es) | 2026-03-02 |
| MX2021008696A (es) | 2021-08-19 |
| TW202042815A (zh) | 2020-12-01 |
| CN113423401A (zh) | 2021-09-21 |
| KR20210119457A (ko) | 2021-10-05 |
| WO2020154252A1 (en) | 2020-07-30 |
| CN118662512A (zh) | 2024-09-20 |
| AU2020213265B2 (en) | 2025-01-16 |
| AU2025201888A1 (en) | 2025-04-03 |
| JP2022523018A (ja) | 2022-04-21 |
| CA3125236A1 (en) | 2020-07-30 |
| US12544372B2 (en) | 2026-02-10 |
| JP2026041743A (ja) | 2026-03-10 |
| EP3914250A1 (en) | 2021-12-01 |
| US20220047588A1 (en) | 2022-02-17 |
| CN118453606A (zh) | 2024-08-09 |
| JP2024099575A (ja) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3788047T3 (da) | Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf | |
| IL281225A (en) | Improved support bases, adapters for them and systems and methods related to them | |
| DK4175951T3 (da) | Hpk1-hæmmere og anvendelser | |
| IL270490B (en) | kras g12c inhibitors and methods of using them | |
| IL280319A (en) | Foundations with screw supports and related systems, methods and machines | |
| DK3985986T3 (da) | Systemer og fremgangsmåder til at ændre størrelsen af indhold baseret på indholdets relative betydning | |
| BR112017002594A2 (pt) | compostos inibidores de cinase de ligação de tank | |
| DK3691620T3 (da) | P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd | |
| EP3740207A4 (en) | CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS | |
| EP3509948A4 (en) | METHODS AND SYSTEMS FOR DAMPING VIBRATION OF A PAYLOAD | |
| EP3445764A4 (en) | DEGRADATION OF CYCLINE-DEPENDENT KINASE 8 (CDK8) BY CONJUGATING CDK9 INHIBITORS WITH E3 LIGASE LIGAND AND METHOD FOR USE THEREOF | |
| IL281060A (en) | Systems and methods of optimal metrology guidance | |
| PH12019501289A1 (en) | Asset transfer method and apparatus, and electronic device | |
| DK3984523T3 (da) | Crf1-receptorantagonist, farmaceutiske formuleringer og faste former heraf til behandling af medfødt binyrebarkhyperplasi | |
| SG11202103142TA (en) | Heterocyclic kinase inhibitors and uses thereof | |
| IL284636A (en) | Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefore | |
| EP3891152A4 (en) | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS RELATED | |
| DK3465202T3 (da) | Massespektrometrifremgangsmåde til detektering og kvantitering af metabolitter | |
| DK3595665T3 (da) | Dobbelthæmmere af magl og faah | |
| EP3573619A4 (en) | THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS | |
| DK3404258T3 (da) | Systemer og fremgangsmåder til stabilisering af effektgenerering | |
| IL284779A (en) | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase | |
| LT3972603T (lt) | Sjogreno sindromo gydymo būdai naudojant brutono tirozino kinazės inhibitorių | |
| EP3543239C0 (en) | SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE | |
| IL285893A (en) | Scalable floating micro-aeration unit, devices and methods |